CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Sanofi India denies reports of Lantus sale, calls media reports ‘unfounded’ The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to ...

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

GoodRx has announced a collaboration with Sanofi to offer the drugmaker’s Lantus brand of insulin for $35 a month at tens of thousands of U.S. pharmacies, regardless of consumers’ insurance ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

Sanofi announced on March 16, 2023 that it will cut the US list price of Lantus (insulin glargine injection) 100 units/mL, a widely prescribed insulin, by 78%. The company will also establish a $35 ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it ...

Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent. The company also will establish a ...

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .

Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.